Generics - North America, Financial


Current filters:

North AmericaFinancial

Popular Filters

1 to 25 of 32 results

Teva agrees $27.6 million settlement with US Justice Dept

Teva agrees $27.6 million settlement with US Justice Dept


US subsidiaries of Israeli generics giant Teva Pharmaceutical Industries have agreed to pay the US government…

ClozapineFinancialGenericsIvaxLegalNeurologicalNorth AmericaTeva Pharmaceutical IndustriesUSA

New data shows FDA’s proposed generic labeling rules would add to health costs

New data shows FDA’s proposed generic labeling rules would add to health costs


The US Food and Drug Administration’s Proposed Rule on prescription drug labeling would add $4 billion…

FinancialGenericsNorth AmericaRegulationUSA

US national health spending growth remains low for 4th consecutive year


Overall national health expenditures in the USA grew at an annual rate of 3.7% in 2012, marking the fourth…

FinancialGenericsHealthcareNorth AmericaPharmaceuticalUSA

AstraZeneca wins damages from Apotex

AstraZeneca wins damages from Apotex


Anglo-Swedish drug major AstraZeneca this morning said it welcomed the US District Court for the Southern…

ApotexAstraZenecaFinancialGastro-intestinalsGenericsNexium I.V.North AmericaPatentsPrilosec

Actavis cuts 350 sales staff after acquisition of Warner Chilcott

Actavis cuts 350 sales staff after acquisition of Warner Chilcott


US generics major Actavis (NYSE: ACT) says it has completed the restructuring of its US Specialty Brands…

ActavisFinancialGenericsManagementNorth AmericaUSAWarner Chilcott

Drug swap drives down costs for US Medicare


Therapeutic drug substitutions have the potential to double or even triple annual cost savings compared…

FinancialGenericsHealthcareNorth AmericaPricing

US FDA jacks up FY 2014 generic drug user fees


In a Federal Register notice, the US Food and Drug Administration has announced the rate for the Abbreviated…

FinancialGenericsNorth AmericaRegulation

Pharma associations strongly support Senate bill on FDA User Fees sequestration exemptions


In the USA last week, Mark Pryor (Democrat, Arkansas), chairman of the Senate Appropriations Subcommittee…

BiotechnologyFinancialGenericsLegalNorth AmericaPharmaceuticalPolitics

Highs and lows as Actavis 2nd qtr results meet expectations


US generics drug major Actavis (NYSE: ACT) reported its net revenue increased 46.8% to $1.99 billion…

ActavisFinancialGenericsNorth AmericaWarner Chilcott

US pharma patent settlements netted $25.5 billion in savings for health system; report


Generic pharmaceuticals launched prior to patent expiration due to a patent settlement - also called…

FinancialGenericsNorth AmericaPatentsPharmaceutical

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds


Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Tightening health budgets on both sides of the Atlantic leading to crackdowns on patent settlements, says EIU analyst


Later this month, following an inquiry launched in 2009, the European Commission is expected to impose…

EuropeFinancialGenericsNorth AmericaPatentsPharmaceuticalPoliticsRegulation

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements


In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Total real per capita spending on medicines in the USA fell 3.5% in 2012


Total spending on US medicines fell 3.5 percent on a real per capita basis in 2012 and the use of health…

FinancialGenericsHealthcareNorth AmericaPharmaceutical

Adherence to generic cholesterol-lowering drugs linked to fall in total care costs


People who regularly take statins to reduce high cholesterol will see lower hospitalization rates according…

Cardio-vascularFinancialGenericsMarkets & MarketingNorth America

Par Pharma agrees $45 million settlement over off-label Megace ES promotion


US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Mixed views from PhRMA and GPhA on Obama's State of the Union Address


There were mixed reactions from two sides of the US drug industry - research-based and generic drugmakers…

FinancialGenericsHealthcareNorth AmericaPharmaceuticalPolitics

US FDA details Generic Drug User Fee for APIs and finished dosage form facilities for FY2013


In a federal Register posting, the US Food and Drug Administration has announced the rate for the generic…

FinancialGenericsNorth AmericaProductionRegulation

US physician acquiescence to patient demands for brand-name drugs, slammed in JAMA article


Prescribing brand-name drugs when generic drugs are available generates unnecessary medical expenditures…

FinancialGenericsHealthcareNorth AmericaPharmaceuticalPricing

Medicines for normal aging conditions overtakes costs of treating most chronic diseases; Express Scripts


In the USA, prescription-drug treatment regimens for conditions that are a normal part of aging are now…

BiotechnologyFinancialGenericsHealthcareNorth AmericaPharmaceutical

Legislative fix would allow FDA to collect GDUFA user fees


Legislation allowing the US Food and Drug Administration to collect several user fees under the Generic…

FinancialGenericsNorth AmericaRegulation

US Medicare prescription drug premiums to remain steady for third straight year


Average basic premiums for Medicare prescription drug plans in the USA are projected to remain constant…

FinancialGenericsHealthcareNorth AmericaPharmaceuticalPricing

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva


US health care giant Johnson & Johnson (NYSE: JNJ) has reached "an agreement in principle'' with the…

FinancialGenericsInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalTeva Pharmaceutical Industries

Mylan settles Provigil litigation with Teva


US generic major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Pharmaceuticals has resolved all…

CephalonFinancialGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaProvigilTeva Pharmaceutical Industries

1 to 25 of 32 results

Back to top